Iberdomide + Daratumumab More Than Doubles MRD-Negative Rates in Myeloma -EXCALIBER | IMS 2026

Sagar Lonial, MD, of Winship Cancer Institute of Emory University discusses the phase 3 EXCALIBER-RRMM trial of iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone at IMS 2026 in Glasgow. He explains how the iberdomide combination more than doubled MRD-negative rates and why using MRD at about one year as an approval endpoint could bring new drugs to patients sooner. He also describes what makes CELMoDs, this new class of drugs, different.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.